Ingenuity Pathway Analysis of sorted CD8+ T cells from LCMV-infected Prf1−∕− mice that were or were not treated with ruxolitinib
| Upstream regulator . | Activation z score . | P value of overlap . |
|---|---|---|
| TREM1 | 2.53 | 1.35E-02 |
| TGFB3 | 2.372 | 4.31E-02 |
| MAP3K14 | 2.213 | 5.38E-03 |
| E2F1 | 2.083 | 3.50E-02 |
| MYOCD | 2 | 9.98E-02 |
| IFNG | −3.075 | 1.92E-07 |
| STAT1 | −2.972 | 2.45E-03 |
| IRF1 | −2.514 | 3.97E-04 |
| IL27 | −2.445 | 7.33E-03 |
| CEBPA | −2.423 | 1.34E-02 |
| CEBPB | −2.315 | 5.04E-03 |
| IL13 | −2.239 | 9.16E-06 |
| NOG | −2.219 | 1.20E-02 |
| EBI3 | −2.216 | 4.32E-03 |
| IL15 | −2.064 | 3.25E-02 |
| Upstream regulator . | Activation z score . | P value of overlap . |
|---|---|---|
| TREM1 | 2.53 | 1.35E-02 |
| TGFB3 | 2.372 | 4.31E-02 |
| MAP3K14 | 2.213 | 5.38E-03 |
| E2F1 | 2.083 | 3.50E-02 |
| MYOCD | 2 | 9.98E-02 |
| IFNG | −3.075 | 1.92E-07 |
| STAT1 | −2.972 | 2.45E-03 |
| IRF1 | −2.514 | 3.97E-04 |
| IL27 | −2.445 | 7.33E-03 |
| CEBPA | −2.423 | 1.34E-02 |
| CEBPB | −2.315 | 5.04E-03 |
| IL13 | −2.239 | 9.16E-06 |
| NOG | −2.219 | 1.20E-02 |
| EBI3 | −2.216 | 4.32E-03 |
| IL15 | −2.064 | 3.25E-02 |